HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bagby, G. C. Articles by Meyers, G. Search for Related Content PubMed PubMed Citation Articles by Bagby, G. C. Articles by Meyers, G. Social Bookmarking                   What's this?

Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention

Correspondence: Grover Bagby, MD, OHSU Cancer Institute, Oregon Health & Sciences University, 3181 SW Sam Jackson Park Road, CR-145, Portland, OR 97239; phone (503) 494-0524; fax (503) 494-7086; grover{at}ohsu.edu

Abstract

Patients with bone marrow failure syndromes are at risk for the development of clonal neoplasms, including paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia (MDS), and acute myelogenous leukemia (AML). Approximately 10% to 20% of those who survive acquired aplastic anemia will develop a clonal disease within the decade following their diagnosis. The relative risk of clonal neoplasms is very significantly increased in children and adults with inherited bone marrow failure syndromes as well. Until recently, the mechanisms underlying clonal evolution have been opaque, but a sufficient amount of evidence has now accumulated to support a model in which cells resistant to extracellular apoptotic cues are selected from the stem cell pool. Indeed, in the past two years this paradigm has been validated in preclinical models that are robust enough to reconsider new therapeutic objectives in aplastic states and to support the planning and development of rationally designed leukemia prevention trials.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?